CA2454762A1 - Isoxazolopyridinones - Google Patents

Isoxazolopyridinones Download PDF

Info

Publication number
CA2454762A1
CA2454762A1 CA002454762A CA2454762A CA2454762A1 CA 2454762 A1 CA2454762 A1 CA 2454762A1 CA 002454762 A CA002454762 A CA 002454762A CA 2454762 A CA2454762 A CA 2454762A CA 2454762 A1 CA2454762 A1 CA 2454762A1
Authority
CA
Canada
Prior art keywords
4alkyl
phenyl
compound
4alkoxy
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002454762A
Other languages
English (en)
French (fr)
Inventor
Samuel Hintermann
Bastian Hengerer
Ulrike Von Krosigk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2454762A1 publication Critical patent/CA2454762A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CA002454762A 2001-08-15 2002-08-14 Isoxazolopyridinones Abandoned CA2454762A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0119911.6 2001-08-15
GBGB0119911.6A GB0119911D0 (en) 2001-08-15 2001-08-15 Organic Compounds
PCT/EP2002/009134 WO2003015780A2 (en) 2001-08-15 2002-08-14 Isoxazolopyridinones and use thereof in the treatment of parkinson's disease

Publications (1)

Publication Number Publication Date
CA2454762A1 true CA2454762A1 (en) 2003-02-27

Family

ID=9920454

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002454762A Abandoned CA2454762A1 (en) 2001-08-15 2002-08-14 Isoxazolopyridinones

Country Status (24)

Country Link
US (1) US7087756B2 (enExample)
EP (1) EP1418912B1 (enExample)
JP (1) JP2005501847A (enExample)
KR (1) KR20040029429A (enExample)
CN (1) CN100384418C (enExample)
AR (1) AR036351A1 (enExample)
AT (1) ATE355059T1 (enExample)
BR (1) BR0211903A (enExample)
CA (1) CA2454762A1 (enExample)
CO (1) CO5560566A2 (enExample)
DE (1) DE60218484T2 (enExample)
EC (1) ECSP044971A (enExample)
ES (1) ES2282467T3 (enExample)
GB (1) GB0119911D0 (enExample)
HU (1) HUP0401325A3 (enExample)
IL (1) IL160018A0 (enExample)
MX (1) MXPA04001419A (enExample)
NO (1) NO20040659L (enExample)
PE (1) PE20030356A1 (enExample)
PL (1) PL366848A1 (enExample)
PT (1) PT1418912E (enExample)
RU (1) RU2004107847A (enExample)
WO (1) WO2003015780A2 (enExample)
ZA (1) ZA200400525B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1408042A4 (en) * 2001-06-14 2005-02-02 Banyu Pharma Co Ltd NEW ISOXAZOLOPYRIDONE DERIVATIVES AND THEIR USE
US7820705B2 (en) * 2004-05-14 2010-10-26 Irm Llc Compounds and compositions as PPAR modulators
AU2007217892A1 (en) * 2006-02-16 2007-08-30 The Mclean Hospital Corporation Methods and compositions for the treatment of Parkinson's Disease
EP2051977A2 (en) 2006-07-20 2009-04-29 Amgen Inc. SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF LLbeta-HSD-1
FR2906250B1 (fr) * 2006-09-22 2008-10-31 Sanofi Aventis Sa Derives de 2-aryl-6phenyl-imidazo(1,2-a) pyridines, leur preparation et leur application en therapeutique
FR2933609B1 (fr) * 2008-07-10 2010-08-27 Fournier Lab Sa Utilisation de derives d'indole comme activateurs de nurr-1, pour le traitement de la maladie de parkinson.
US8173670B2 (en) * 2009-01-13 2012-05-08 Van Andel Research Institute Methods of using substituted isoxazolo pyridinones as dissociated glucocorticoids
FR2950053B1 (fr) 2009-09-11 2014-08-01 Fournier Lab Sa Utilisation de derives d'indole benzoique comme activateurs de nurr-1, pour le traitement de la maladie de parkinson
FR2955110A1 (fr) 2010-01-08 2011-07-15 Fournier Lab Sa Nouveaux derives de type pyrrolopyridine benzoique
DE102011085038A1 (de) 2011-10-21 2013-04-25 Tesa Se Verfahren zur Kapselung einer elektronischen Anordnung
EP3049089B1 (en) 2013-09-25 2019-08-21 Van Andel Research Institute Highly potent glucocorticoids
KR20170033630A (ko) 2015-09-17 2017-03-27 (주)다올 도로용 경계블럭
EP3525870B1 (en) 2016-10-14 2023-05-10 Van Andel Research Institute Highly potent glucocorticoids

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7602542L (sv) 1975-03-14 1976-09-15 Sandoz Ag 3-(alfa-iminobensyl)-4-hydroxi-2(lh)-pyridoner
US4064251A (en) * 1976-06-25 1977-12-20 Sandoz, Inc. Substituted hydroxy pyridones
US4049813A (en) * 1976-07-15 1977-09-20 Sandoz, Inc. Substituted isoxazolo pyridinones
DE2801190A1 (de) * 1977-01-19 1978-07-20 Sandoz Ag 3-(alpha-iminobenzyl)-4-hydroxy-2(1h)- pyridon-derivat
US4238616A (en) * 1977-01-19 1980-12-09 Sandoz, Inc. 3-(Substituted)phenyl-5-(β-hydroxyphenethyl)-N-(alkyl)-isoxazole-4-carboxamides
US4113727A (en) * 1977-04-26 1978-09-12 Sandoz, Inc. Process for the preparation of substituted isoxazolo[4,5-c]pyridin-4-(5H)-ones
EP1408042A4 (en) * 2001-06-14 2005-02-02 Banyu Pharma Co Ltd NEW ISOXAZOLOPYRIDONE DERIVATIVES AND THEIR USE

Also Published As

Publication number Publication date
RU2004107847A (ru) 2005-05-10
ECSP044971A (es) 2004-03-23
PE20030356A1 (es) 2003-05-14
CN100384418C (zh) 2008-04-30
EP1418912A2 (en) 2004-05-19
ES2282467T3 (es) 2007-10-16
BR0211903A (pt) 2004-09-21
WO2003015780A8 (en) 2004-05-21
ATE355059T1 (de) 2006-03-15
CN1635889A (zh) 2005-07-06
NO20040659D0 (no) 2004-02-13
EP1418912B1 (en) 2007-02-28
ZA200400525B (en) 2005-04-01
GB0119911D0 (en) 2001-10-10
PT1418912E (pt) 2007-05-31
MXPA04001419A (es) 2004-05-27
HUP0401325A3 (en) 2005-09-28
WO2003015780A3 (en) 2003-11-13
US7087756B2 (en) 2006-08-08
JP2005501847A (ja) 2005-01-20
KR20040029429A (ko) 2004-04-06
AR036351A1 (es) 2004-09-01
NO20040659L (no) 2004-02-13
HUP0401325A2 (hu) 2004-10-28
PL366848A1 (en) 2005-02-07
WO2003015780A2 (en) 2003-02-27
DE60218484T2 (de) 2007-11-15
IL160018A0 (en) 2004-06-20
DE60218484D1 (de) 2007-04-12
US20040248893A1 (en) 2004-12-09
CO5560566A2 (es) 2005-09-30

Similar Documents

Publication Publication Date Title
CN106661002B (zh) 用于治疗炎性、代谢性、肿瘤性和自身免疫性疾病的嘧啶衍生物
AU2004212151B2 (en) Heterocyclic compounds useful as Nurr-1 activators
US7087756B2 (en) Isoxazolopyridinones
JP2004524317A (ja) アンドロゲン受容体モジュレーター化合物としての三環式キノリノンおよび三環式キノリン
TW200400963A (en) R-enantiomers of pyranoindole derivatives and the use thereof for the treatment of hepatitis C virus infection or disease
TW200804378A (en) Organic compounds
CN1042225C (zh) 新的取代的异噁唑衍生物的制备方法
US20060111386A1 (en) Novel 4-phenyl substituted tetrahydroisoquinolines and therapeutic use thereof
WO2020156479A1 (zh) 环丙烯并苯并呋喃取代的氮杂芳基化合物、其中间体、制备方法及应用
JP2022523668A (ja) Ｍａｇｌ阻害剤による疾病の治療方法
CN114656472B (zh) 吡唑并嘧啶类化合物、异构体或盐及其制备方法和用途
DK2546255T3 (en) benzazepine
JP2017527573A (ja) 糖尿病の治療用の選択的ＮａＶ１．７阻害剤
CN112759588B (zh) 苯并五元杂环胺类衍生物及其用途
MXPA04007738A (es) 2-oxazolaminas y su uso como antagonistas del receptor 5-ht2b.
CN114891003B (zh) 新型二氢嘧啶类化合物、中间体或盐及其制备方法和用途
AU2002336977A1 (en) Isoxazolopyridinones and use thereof in the treatment of Parkinson's disease
EP3621620A1 (en) Substituted heterocyclic compounds as allosteric modulators of group ii metabotropic glutamate receptors
CN115611877A (zh) 磺酰胺类化合物、其制备方法及其在医药上的应用
CN114656480B (zh) 噻吩并嘧啶类化合物、异构体或盐及其制备方法和用途
WO2005016255A2 (en) Substituted tetrahydroquinolines, phenylacetic acids and benzoic acids as hepatocyte nuclear factor 4 (hnf-4 ) modulator compounds
CN114656473B (zh) 吡咯并嘧啶类化合物、异构体或盐及其制备方法和用途
CN114671876B (zh) 新型茶碱类化合物、异构体或盐及其制备方法和用途
CN116535424A (zh) 作为malt1抑制剂的三并环化合物及其药物组合物和应用

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued